These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 12356195)

  • 1. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.
    Russell R; Brookshire MA; Zekonis M; Moe SM
    Clin Nephrol; 2002 Sep; 58(3):238-43. PubMed ID: 12356195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies.
    Don BR; Chin AI
    Clin Nephrol; 2003 Jun; 59(6):463-70. PubMed ID: 12834180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification.
    Paret CL
    J Ren Nutr; 2003 Oct; 13(4):288-94. PubMed ID: 14566766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
    Qunibi WY; Hootkins RE; McDowell LL; Meyer MS; Simon M; Garza RO; Pelham RW; Cleveland MV; Muenz LR; He DY; Nolan CR
    Kidney Int; 2004 May; 65(5):1914-26. PubMed ID: 15086935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.
    Hervás JG; Prados D; Cerezo S
    Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J; Asmus HG; Holzer H; Brunkhorst R; Krause R; Schulz W; Neumayer HH; Raggi P; Bommer J
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
    Chertow GM; Dillon MA; Amin N; Burke SK
    J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR; Qunibi WY
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
    Cozzolino M; Dusso AS; Liapis H; Finch J; Lu Y; Burke SK; Slatopolsky E
    J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healing of skin necrosis and regression of anticardiolipin antibodies achieved by parathyroidectomy in a dialyzed woman with calcific uremic arteriolopathy.
    Sefer S; Trotić R; Degoricija V; Vrsalović M; Ratković-Gusić I; Kes P
    Croat Med J; 2001 Dec; 42(6):679-82. PubMed ID: 11740855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.